Adicet Bio, Inc. Research and Development Expense
Adicet Bio, Inc. (ACET) reported Research and Development Expense of $18.45 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- Adicet Bio, Inc. research and development expense for the quarter ending 2026-06-30 was $18.45M, a 35.09% decline year-over-year.
- Adicet Bio, Inc. research and development expense for the quarter ending 2026-03-31 was $17.49M, a 23.35% decline year-over-year.
- Adicet Bio, Inc. research and development expense for the quarter ending 2025-12-31 was $25.04M, a 7.58% increase year-over-year.
- Adicet Bio, Inc. research and development expense for the quarter ending 2025-09-30 was $22.85M, a 12.95% decline year-over-year.
- Adicet Bio, Inc. research and development expense for fiscal 2025 was $99.13M, a 0.20% decline from fiscal 2024.
- Adicet Bio, Inc. research and development expense for fiscal 2024 was $99.32M, a 6.34% decline from fiscal 2023.
- Adicet Bio, Inc. research and development expense for fiscal 2023 was $106.04M, a 48.84% increase from fiscal 2022.
- Adicet Bio, Inc. research and development expense for fiscal 2022 was $71.25M, a 45.57% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $18.45M 10-Q · filed 2026-08-05 | $35.94M 10-Q · filed 2026-08-05 | $60.97M derived: sum of 3 quarters · filed 2026-08-05 | $83.83M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $17.49M 10-Q · filed 2026-05-13 | $42.52M derived: sum of 2 quarters · filed 2026-05-13 | $65.38M derived: sum of 3 quarters · filed 2026-05-13 | $93.80M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $25.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $47.89M derived: sum of 2 quarters · filed 2026-03-12 | $76.31M derived: sum of 3 quarters · filed 2026-08-05 | $99.13M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $22.85M 10-Q · filed 2025-11-05 | $51.28M derived: sum of 2 quarters · filed 2026-08-05 | $74.09M 10-Q · filed 2025-11-05 | $97.36M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $28.42M 10-Q · filed 2026-08-05 | $51.24M 10-Q · filed 2026-08-05 | $74.51M derived: sum of 3 quarters · filed 2026-08-05 | $100.76M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $22.81M 10-Q · filed 2026-05-13 | $46.09M derived: sum of 2 quarters · filed 2026-05-13 | $72.34M derived: sum of 3 quarters · filed 2026-05-13 | $98.24M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $23.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $49.53M derived: sum of 2 quarters · filed 2026-03-12 | $75.43M derived: sum of 3 quarters · filed 2026-03-12 | $99.32M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $26.25M 10-Q · filed 2025-11-05 | $52.15M derived: sum of 2 quarters · filed 2025-11-05 | $76.05M 10-Q · filed 2025-11-05 | $100.81M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $25.90M 10-Q · filed 2025-08-07 | $49.80M 10-Q · filed 2025-08-07 | $74.56M derived: sum of 3 quarters · filed 2025-08-07 | $100.72M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $23.90M 10-Q · filed 2025-05-06 | $48.66M derived: sum of 2 quarters · filed 2025-05-06 | $74.82M derived: sum of 3 quarters · filed 2025-05-06 | $103.19M derived: sum of 4 quarters · filed 2025-05-06 | ||||
| 2023-12-31 | $24.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $50.93M derived: sum of 2 quarters · filed 2025-03-06 | $79.29M derived: sum of 3 quarters · filed 2025-03-06 | $106.04M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | $26.17M 10-Q · filed 2024-11-06 | $54.53M derived: sum of 2 quarters · filed 2024-11-06 | $81.28M 10-Q · filed 2024-11-06 | $106.30M derived: sum of 4 quarters · filed 2024-11-06 | ||||
| 2023-06-30 | $28.36M 10-Q · filed 2024-08-13 | $55.12M 10-Q · filed 2024-08-13 | $80.13M derived: sum of 3 quarters · filed 2024-08-13 | $96.70M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $26.76M 10-Q · filed 2024-05-14 | $51.77M derived: sum of 2 quarters · filed 2024-05-14 | $68.34M derived: sum of 3 quarters · filed 2024-05-14 | $84.52M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $25.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $41.59M derived: sum of 2 quarters · filed 2024-03-19 | $57.76M derived: sum of 3 quarters · filed 2024-03-19 | $71.25M 10-K · filed 2024-03-19 | ||||
| 2022-09-30 | $16.57M 10-Q · filed 2023-11-08 | $32.75M derived: sum of 2 quarters · filed 2023-11-08 | $46.23M 10-Q · filed 2023-11-08 | $60.89M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $16.18M 10-Q · filed 2023-08-09 | $29.66M 10-Q · filed 2023-08-09 | $44.32M derived: sum of 3 quarters · filed 2023-08-09 | $56.24M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $13.48M 10-Q · filed 2023-05-09 | $28.14M derived: sum of 2 quarters · filed 2023-05-09 | $40.07M derived: sum of 3 quarters · filed 2023-05-09 | $50.68M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $14.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $26.58M derived: sum of 2 quarters · filed 2023-03-15 | $37.20M derived: sum of 3 quarters · filed 2023-03-15 | $48.94M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | $11.93M 10-Q · filed 2022-11-08 | $22.54M derived: sum of 2 quarters · filed 2022-11-08 | $34.28M 10-Q · filed 2022-11-08 | $43.97M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $10.62M 10-Q · filed 2022-08-10 | $22.36M 10-Q · filed 2022-08-10 | $32.04M derived: sum of 3 quarters · filed 2022-08-10 | $40.98M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | $11.74M 10-Q · filed 2022-05-12 | $21.43M derived: sum of 2 quarters · filed 2022-05-12 | $30.37M derived: sum of 3 quarters · filed 2022-05-12 | $39.04M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $9.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $18.63M derived: sum of 2 quarters · filed 2022-03-15 | $27.30M derived: sum of 3 quarters · filed 2022-03-15 | $34.33M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | $8.94M 10-Q · filed 2021-11-10 | $17.62M derived: sum of 2 quarters · filed 2021-11-10 | $24.65M 10-Q · filed 2021-11-10 | $31.17M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $8.68M 10-Q · filed 2021-08-12 | $1.79M 10-Q · filed 2020-07-30 | $15.71M 10-Q · filed 2021-08-12 | $6.63M 10-Q · filed 2020-07-30 | $22.23M derived: sum of 3 quarters · filed 2021-08-12 | $28.56M derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | $7.03M 10-Q · filed 2021-05-17 | $4.84M 10-Q · filed 2020-05-07 | $13.56M derived: sum of 2 quarters · filed 2021-05-17 | $19.89M derived: sum of 3 quarters · filed 2021-05-17 | $36.44M derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2019-12-31 | $6.52M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $12.85M derived: sum of 2 quarters · filed 2021-03-12 | $29.41M derived: sum of 3 quarters · filed 2021-03-12 | $23.69M 10-K · filed 2021-03-12 | $73.63M 10-K · filed 2020-03-12 | |||
| 2019-09-30 | $6.33M 10-Q · filed 2020-11-05 | $22.12M 10-Q · filed 2019-11-05 | $22.88M derived: sum of 2 quarters · filed 2020-11-05 | $17.17M 10-Q · filed 2020-11-05 | $47.52M 10-Q · filed 2019-11-05 | $19.74M derived: sum of 4 quarters · filed 2021-03-12 | ||
| 2019-06-30 | $16.55M 10-Q · filed 2020-07-30 | $25.41M 10-Q · filed 2020-07-30 | $13.41M derived: sum of 3 quarters · filed 2021-03-12 | $20.17M derived: sum of 4 quarters · filed 2021-03-12 | ||||
| 2019-03-31 | $8.85M 10-Q · filed 2020-05-07 | -$3.15M derived: sum of 2 quarters · filed 2021-03-12 | $3.62M derived: sum of 3 quarters · filed 2021-03-12 | $15.46M derived: sum of 4 quarters · filed 2021-03-12 | ||||
| 2018-12-31 | -$12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$5.23M derived: sum of 2 quarters · filed 2021-03-12 | $6.61M derived: sum of 3 quarters · filed 2021-03-12 | $14.72M 10-K · filed 2021-03-12 | $31.07M 10-K · filed 2019-03-18 | |||
| 2018-09-30 | $6.76M 10-Q · filed 2019-11-05 | $18.61M derived: sum of 2 quarters · filed 2019-11-05 | $26.72M 10-Q · filed 2019-11-05 | $33.51M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-06-30 | $11.85M 10-Q · filed 2019-08-14 | $19.95M 10-Q · filed 2019-08-14 | $26.74M derived: sum of 3 quarters · filed 2020-03-12 | $30.08M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-03-31 | $8.11M 10-Q · filed 2019-05-15 | $14.90M derived: sum of 2 quarters · filed 2020-03-12 | $18.23M derived: sum of 3 quarters · filed 2020-03-12 | $21.65M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2017-12-31 | $6.79M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $10.13M derived: sum of 2 quarters · filed 2020-03-12 | $13.54M derived: sum of 3 quarters · filed 2020-03-12 | $16.84M 10-K · filed 2020-03-12 | ||||
| 2017-09-30 | $3.33M 10-Q · filed 2018-11-13 | $6.75M derived: sum of 2 quarters · filed 2018-11-13 | $10.05M 10-Q · filed 2018-11-13 | |||||
| 2017-06-30 | $3.42M 10-Q · filed 2018-08-09 | $6.71M 10-Q · filed 2018-08-09 | ||||||
| 2017-03-31 | $3.29M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |